Harmony Biosciences Holdings (HRMY) Income from Continuing Operations (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Income from Continuing Operations data on file, last reported at 32488000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 28.69% year-over-year to 32488000.0; the trailing twelve-month figure through Mar 2026 stood at 188391000.0 (up 23.36% YoY), and the FY2025 full-year result was 201463000.0, up 38.47% from the prior year.
• Income from Continuing Operations fell to 32488000.0 in Q1 2026, from 65262000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 87943000.0 in Q3 2022 to a low of 11591000.0 in Q2 2024.
• A 5-year average of 40574411.76 and a median of 38461000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations surged 1014.17% in 2022 and sank 66.21% in 2024, its largest moves.
• Tracing HRMY's Income from Continuing Operations over 5 years: stood at 48509000.0 in 2022, then slumped by 45.15% to 26607000.0 in 2023, then surged by 85.95% to 49475000.0 in 2024, then soared by 31.91% to 65262000.0 in 2025, then plunged by 50.22% to 32488000.0 in 2026.
• Business Quant data shows HRMY's Income from Continuing Operations at 32488000.0 in Q1 2026, 65262000.0 in Q4 2025, and 50865000.0 in Q3 2025.